Risk of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Addition of SGLT2 Inhibitors Versus Sulfonylureas to Baseline GLP-1RA Therapy

Authors: Chintan V. Dave, Seoyoung C. Kim, Allison B. Goldfine, Robert J. Glynn, Angela Tong, Elisabetta Patorno

Published: 2020-12-11

DOI: 10.1161/circulationaha.120.047965

Source: Full article

---

Abstract

Background: